Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer

Gynecologic Oncology

Volumn 63, Issue 3, 1996, Pages 323-327

  Fanning, James ^a   Hilgers, Robert D ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MAGNESIUM; MANNITOL; MESNA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; THROMBOCYTOPENIA;

EID: 0030561573     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0330     Document Type: Article

References (20)

1. 1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1996, Ca Cancer J. Clin. 65, 5-27 (1996).
2. 2. Fanning, J., Piver, M. S., and Sprance, H. E. Five-year survival for cisplatin-based chemotherapy versus single-agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery, J. Surg. Oncol. 48, 33 (1991).
3. 3. Pekka, V. Epithelial ovarian cancer: Impact of surgery and chemotherapy on survival during 1977-1990, Obstet. Gynecol. 84, 8-11 (1994).
4. 4. Fanning, J., and Hilgers, R. D. Technology to intensify cytoreduction of ovarian cancer, Contemp. Obstet. Gynecol. 39, 72-82 (1994).
5. 5. Fanning, J., Hilgers, R. D., Richards, P. K., and Hunt, K. D. Carbon dioxide laser vaporization of intestinal metastasis of epithelial ovarian cancer, Int. J. Gynecol. Oncol. 4, 324-327 (1994).
6. 6. Fanning, J., and Hilgers, R. D. Loop electrosurgical excision procedure for intensified cytoreduction of ovarian cancer, Gynecol. Oncol. 57, 188-190 (1995).
7. 7. The American Society of Clinical Oncology, American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines, J. Clin. Oncol. 12, 2471-2508 (1994).
8. 8. Levin, L., and Hryniuk, W. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma, J. Clin. Oncol. 5, 756-767 (1987).
9. 9. McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., and Berman, M. L. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study, J. Clin. Oncol. 13, 1589-1599 (1995).
10. 10. Colombo, N., Pittelli, M., and Parma, G. Cisplatin dose intensity in advanced ovarian cancer: A randomized study of conventional dose versus dose-intense cisplatin monochemotherapy, Proc. ASCO 12, 255 (1993).
11. 11. Kaye, S. B., Paul, J., Cassidy, J., et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer, J. Clin. Oncol. 14, 2113-2119 (1996).
12. 12. Fanning, J., and Hilgers, R. D. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer, Gynecol. Oncol. 51, 182-186 (1993).
13. 13. Fanning, J., Hilgers, R. D., and Hutson, E. Carboplatin, etopiside and ifosfamide as second-line treatment for ovarian cancer, Am. J. Clin. Oncol. 17, 335-337 (1994).
14. 14. Fields, K. K., Zorsky, P. E., Hiemenz, J. W., Kronish, L. E., and lfenbein, G. J. Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity, J. Clin. Oncol. 12, 544-552 (1994).
15. 15. Krigel, R. L., Palackdharry, C. S., Padavic, K., Haas, N., Kilpatrick, D., Langer, C., and Comis, R. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: A phase I study with apparent activity in non-small-cell lung cancer, J. Clin. Oncol. 12, 1251-1258 (1994).
16. 16. International Federation of Gynecology and Obstetrics (FIGO). Changes in gynecologic cancer staging by the International Federation of Gynecology and Obstetrics, Am. J. Obstet. Gynecol. 162, 610 (1990).
17. 17. Calvert, A. H., Lind, M. J., Ghamal-Aswad, S., Gumbrell, L., Millward, M. J., and Bailey, N. P. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: A phase I dose-intensity escalation study, Semin. Oncol. 21, 1-6 (1994).
18. 18. Reed, E., Janik, J., Bookman, M. A., Rothenberg, M., Smith, J., and Young, R. C. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer, J. Clin. Oncol. 11, 2118-2126 (1993).
19. 19. Rusthoven, J., Levin, L., Eisenhauer, E., Mazurka, J., Carmichael, J., and O'Connell, G. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor, J. Natl. Cancer Inst. 83, 1748-1753 (1991).
20. 20. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., and Look, K. Y. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).